Clarivate Epidemiology’s coverage of acute coronary syndrome (ACS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology’s coverage of ACS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of acute coronary…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key acute coronary syndrome patient populations covering 171 countries…
The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilars developers must ensure that they are equipped with the necessary…
Amgen, Q3 2019 Amgen Earnings Conference Call Presentation. Accessed on October 31, 2019.Baselga J, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEJM. Jan 12;366(…
AbbVie has rigorously defended the IP surrounding its multibillion-dollar product Humira in the United States, resulting in a favorable outcome that is set to prevent biosimilar entry for several…
Biosimilar sponsors are not required to replicate all reference product clinical trials for the approval of their biosimilars via regulatory agencies’ abbreviated pathways. However, they need to…
Spinocerebellar ataxia (SCA) is a heterogeneous group of rare neurodegenerative progressive disorders that primarily affects the cerebellum, and, in some cases, the spinal cord, resulting in the…